Answer
Padcev (enfortumab vedotin) is contraindicated in patients with hypersensitivity to enfortumab vedotin or any of the excipients listed in section 6.1 of its SmPC.
Sources for this answer
- Padcev 20 mg and 30 mg powder for concentrate for solution for infusionAstellas Pharma Ltd · emc · SmPC §4.3 Contraindications · Version 11Document updated
Sources checked